Emgality vs Ubrelvy
Side-by-side cost comparison based on Medicare Part D data
Emgality
Galcanezumab
Manufactured by Eli Lilly
Ubrelvy
Ubrogepant
Manufactured by AbbVie
Ubrelvy costs 56% less per claim than Emgality ($305.00 vs $688.00). A generic version of Ubrelvy is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Emgality | Ubrelvy |
|---|---|---|
| Avg Cost Per Claim | $688.00 | $305.00 |
| Total Medicare Spending | $678.0M | $567.0M |
| Total Beneficiaries | 112,000 | 224,000 |
| Total Claims | 986,000 | 1,860,000 |
| Annual Cost/Patient | $6,054.00 | $2,531.00 |
| Year-over-Year Change | +14.8% | +32.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Eli Lilly | AbbVie |
| Condition | Migraine | Migraine |
| Generic Name | Galcanezumab | Ubrogepant |
Emgality vs Ubrelvy: What the Data Shows
Emgality (Galcanezumab) and Ubrelvy (Ubrogepant) are both used to treat migraine. Based on Medicare Part D data, Ubrelvy costs $305.00 per claim, which is 56% less than Emgality at $688.00 per claim.
Medicare spent $678.0M on Emgality and $567.0M on Ubrelvy. In terms of patient reach, Ubrelvy serves more beneficiaries (224,000 vs 112,000).
Year-over-year spending changed +14.8% for Emgality and +32.4% for Ubrelvy. Emgality saw significant spending growth, suggesting increased utilization or price increases. Ubrelvy saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Ubrelvy is cheaper at $305.00 per claim, compared to $688.00 for Emgality. That makes Ubrelvy about 56% less expensive per claim based on Medicare Part D data.
Yes, both Emgality and Ubrelvy are used to treat migraine. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Galcanezumab and generic Ubrogepant can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $678.0M on Emgality covering 112,000 beneficiaries, and $567.0M on Ubrelvy covering 224,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.